A Trial Comparing the Effectiveness and Tolerability of Medications in Older Adults with Stable Angina and Multiple Chronic Conditions: LIVEBETTER

To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).

For more information, visit: https://clinicaltrials.gov/study/NCT05786417

Inova Schar Cancer Institute
A division of Inova Fairfax Hospital
8081 Innovation Park Drive 
Fairfax, VA 22031

1. Age ≥70 years; ≥65 years for underrepresented minorities (URM) of black race or Hispanic ethnicity
2. ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS)
3. Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following:
   • positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease
   • coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or ≥50% stenosis of left main
   • Invasive coronary angiography with positive physiologic testing in at least one vessel (FFR ≤80 or iFR ≤0.89)

1. Currently taking a beta-blocker or calcium channel blocker*,**
2. Contraindication to beta-blockers or calcium channel blockers including:
   • significant hypotension
   • high grade AV block
   • severe symptomatic bradycardia
   • severe obstructive lung disease
3. Documented intolerance to beta-blockers or calcium channel blockers
4. Clear indication for beta-blockers or calcium channel blockers including:
   • Diagnosis of acute coronary syndrome (ACS) within past year
   • Heart failure with reduced ejection fraction (HFrEF) within past year
5. Plans for complete revascularization within 2 weeks.
6. Primary language other than English or Spanish